This review will concentrate on the clinical pharmacology, in particular pharmacodynamic data, related to atypical antipsychotics, clozapine, risperidone, paliperidone, olanzapine, quetiapine, amisulpride, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone and cariprazine. A summary of their acute pharmacokinetics properties are also reported. Four new second-generation antipsychotics are available: iloperidone, asenapine, lurasidone and in the next future cariprazine. Similar to ziprasidone and aripiprazole, these new agents are advisable for the lower propensity to give weight gain and metabolic abnormalities in comparison with older second-generation antipsychotics such as olanzapine or clozapine. Actually lurasidone seems to be best in terms of minimizing unwanted alterations in body weight and metabolic variables. Therapeutic drug monitoring is not strictly necessary for all of the new antipsychotic drugs because there are no unequivocal data supporting a relationship between plasma drug levels and clinical outcomes or side effects. The exception can be represented by clozapine for which plasma levels of 350-420 ng/ml are reported to be associated with an increased probability of a good clinical response. Also for olanzapine an established therapeutic range (2050 ng/ml) is proposed to yield an optimal response and minimize side effects.

Clinical pharmacology of atypical antipsychotics : an update / M. Mauri, S. Paletta, M. Maffini, A. Colasanti, F. Dragogna, C. Di Pace, A. Altamura. - In: EXCLI JOURNAL. - ISSN 1611-2156. - 13(2014 Oct), pp. 1163-1191.

Clinical pharmacology of atypical antipsychotics : an update

M. Mauri
Primo
;
S. Paletta
Secondo
;
M. Maffini;A. Colasanti;F. Dragogna;C. Di Pace
Penultimo
;
A. Altamura
Ultimo
2014

Abstract

This review will concentrate on the clinical pharmacology, in particular pharmacodynamic data, related to atypical antipsychotics, clozapine, risperidone, paliperidone, olanzapine, quetiapine, amisulpride, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone and cariprazine. A summary of their acute pharmacokinetics properties are also reported. Four new second-generation antipsychotics are available: iloperidone, asenapine, lurasidone and in the next future cariprazine. Similar to ziprasidone and aripiprazole, these new agents are advisable for the lower propensity to give weight gain and metabolic abnormalities in comparison with older second-generation antipsychotics such as olanzapine or clozapine. Actually lurasidone seems to be best in terms of minimizing unwanted alterations in body weight and metabolic variables. Therapeutic drug monitoring is not strictly necessary for all of the new antipsychotic drugs because there are no unequivocal data supporting a relationship between plasma drug levels and clinical outcomes or side effects. The exception can be represented by clozapine for which plasma levels of 350-420 ng/ml are reported to be associated with an increased probability of a good clinical response. Also for olanzapine an established therapeutic range (2050 ng/ml) is proposed to yield an optimal response and minimize side effects.
amisulpride; aripiprazole; asenapine; atypical antipsychotic agent; cariprazine; clozapine; iloperidone; lurasidone; olanzapine; paliperidone; placebo; quetiapine; risperidone; ziprasidone
Settore MED/25 - Psichiatria
ott-2014
Article (author)
File in questo prodotto:
File Dimensione Formato  
MauriAltamura_EXCLI_ClinicalPharmacology_2014_.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 582.93 kB
Formato Adobe PDF
582.93 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/425198
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 210
  • ???jsp.display-item.citation.isi??? 185
social impact